

TB Alliance | Drug development pipeline*

DISCOVERY

EARLY DEVELOPMENT

LATE DEVELOPMENT

LEAD IDENTIFICATION

DnaN
X-Chem

Host-Directed Therapy
DoD
ITHEMYC

PEPCK
UIC

PknB
X-Chem

PknB Protac
DoD

PptT
Evotec
Texas A&M
UNC
WCM

Whole Cell Hit-to-Lead Program
GSK

LEAD OPTIMIZATION

Anti-TB Natural Products
Evotec

ClpC1
Harvard
UIC

ClpP1P2 Programs
GHDDI
Harvard
UIC

Intracellular Active Series
Evotec

Intracellular Active Series
GSK

MmpL3 Inhibitors
Lgenia
GHDDI

RNA Polymerase Inhibitors
Lgenia
UIC

PRECLINICAL DEVELOPMENT

Long-Acting Injectables (LAIs)
Pretomanid
TBAJ-876
TBAJ-587
Q-203

Preclinical TB Regimen Development
ERA4TB
JHU
TBDA
UCSF

PAN-TB Collaboration
BMGF



Scan here for the online portfolio

PHASE 1

PHASE 2

TBAJ-587 /Diarylquinoline
ERA4TB
UNITE4TB

BPaMZ /SEM
UoSA
NCOOS

TBAJ-876 /Diarylquinoline

Q-203
ERA4TB
NCATS
Qurient

Sutezolid / Oxazolidinone
PAN-HM | Aurum
PAN-TB | Gates MRI ,
Janssen, Otsuka
RAD-TB | ACTG

TBA-7371 / DprE1 Inhibitor
FNDR
Gates MRI

TBI-223 / Oxazolidinone
IMM
RAD-TB | ACTG

PHASE 3

Completed

BPaL
bedaquiline + pretomanid + linezolid
Viatrix
NixTB

BPaL
bedaquiline + pretomanid + linezolid
Viatrix
ZeNix

BPaMZ **SIMPLICITB**
bedaquiline + pretomanid + moxifloxacin + pyrazinamide
PanACEA
Radboud
Viatrix

TB Practecal
Innovating MDR-TB Treatment

BPaL/M
bedaquiline + pretomanid + linezolid + moxifloxacin
MSF Amsterdam

MARKETED PRODUCTS

OPTIMIZED PEDIATRIC FORMULATIONS with Macleods
Ethambutol
Isoniazid
Pyrazinamide
Rifampicin / Isoniazid
Rifampicin / Isoniazid / Pyrazinamide

PEDIATRIC FORMULATION DEVELOPMENT
Pretomanid
Viatrix

PRETOMANID FOR USE IN BPaL
Pretomanid for use in BPaL and BPaL/M Regimens
Hongqi
Lupin
Macleods
Remington
Viatrix


*As of March 2026. This document is updated on a quarterly basis.



Beyond NC-009

REPLACING LINEZOLID IN THE REGIMEN - TARGETING NEW PATHWAY


FIVE WAYS TO TARGET TB



Proven pathway
ELECTRON TRANSPORT CHAIN
Stop the generation of cell energy so TB bacteria can't grow

1

2



Proven pathway
CELL WALL DISRUPTION

Weaken cell walls and in the process, destroy TB bacteria

3

New pathway
CENTRAL CARBON METABOLISM
Starve TB bacteria so it can't grow




4



New pathway
PROTEIN DEGRADATION
Poison the cell by inhibiting the ability to eliminate waste

5



New pathway
PROTEIN SYNTHESIS

Block TB's ability to make protein necessary for its survival

Beyond NC-009

REPLACING LINEZOLID IN THE REGIMEN - TARGETING NEW PATHWAY - PROTEOLYSIS

Clp-2157 targets the proteolytic component


Significantly increases the sterilizing activity
of the SPa backbone

As sterilizing as SPaL and SPaM

Addition of ClpP-2157 also significantly
increased the sterilizing activity
of SPaM in a dose-dependent manner

All mice treated with SPaM+ClpP-2157100
were relapse free after 8 weeks of treatment


Clp2157 is currently being evaluated
in non-GLP toxicity studies





S = sorfequiline | **Pa** = pretomanid | **L** = linezolid | **M** = moxifloxacin



Regimen development strategy to shorten duration of treatment



Exploit novel host directed therapies to achieve treatment shortening






Current status and directions

A COMPREHENSIVE APPROACH THAT LEVERAGES AI AND CUTTING-EDGE METHODOLOGIES


CONTINUE EVALUATION OF INVENIAI TOP TARGETS

In partnership with **ITHEMYC**, EU consortium formed to develop innovative adjunctive TB immunotherapies



STRATEGIC APPROACH TO IDENTIFYING MOST PROMISING PATHWAYS

Formed Scientific Advisory Board in 2023 to seek input on HDT strategy



ESTABLISH A COLLABORATIVE PROGRAM


With input from SAB, developed a multi-pronged strategy to target granuloma

TBA formed a collaborative partnership to advance several hypothesis



Host-directed approaches to target granuloma pathways for treatment-shortening in tuberculosis

DOD GRANT AWARDED IN JULY 2023




EVALUATE

the adjunctive potential of granuloma-targeting HDTs with diverse mechanisms of action in mouse models of tuberculosis



SELECT

the most promising HDT for evaluation in NHP model to generate data enabling clinical translation



DATA

integration through modeling to develop translational tools for prediction of clinical efficacy



DEVELOP

a strategy to rank and prioritize compounds with the best clinical potential and establish a critical path for preclinical evaluation and progression of host-directed agents in *in vitro* and *in vivo* models



Artificial intelligence

AI TO SUPPORT IMMUNOTHERAPY

AI driven analysis of immunomodulatory pathways and targets with greatest impact on bacterial clearance



Targets and pathways have either clinical or research compounds available

Select top candidates to evaluate in a relapse mouse model on top of a novel regimen and SOC



AI-ASSISTED SCREENING PROCESS

Combine large scale screening approach (DNA encoded Library) and AI to select advanced drug-like lead



Reduction of cost of goods through shorter and more efficient synthesis

